Novo Nordisk announced it is cutting ties with telehealth giant Hims & Hers Health, pulling its blockbuster drug Wegovy from ...

The FDA has granted accelerated approval of Wegovy® (semaglutide) for adults with moderate to advanced metabolic ...

With results from highly anticipated trials of Eli Lilly’s orforglipron and Viking Therapeutics’ VK2735 “underwhelming” ...

Serena Williams has long been subjected to ill-tasted criticism over her weight. Her recent collaboration with a healthy ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

Imagine losing weight effortlessly! Chinese scientists have developed flavorless, fat-trapping microbeads made from green tea ...

Margolyes has long discussed her health conditions, including spinal stenosis and osteoporosis. According to Mayo Clinic, ...

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...

Eli Lilly and Company LLY is a key player in the diabetes and obesity drug market, mainly due to the significant popularity ...

Discover why Hims & Hers Health's subscriber growth, profitability, and telehealth expansion make it a strong buy with a ...

In the wake of weight-loss drugs and the rising importance of health, the iconic cultural brand must double down on its roots ...

The Dow Jones and S&P 500 jumped Friday to record highs on Fed chief Jerome Powell's dovish Jackson Hole speech.